Bupivacaine for Postoperative Pain

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Postoperative Pain+1 MoreBupivacaine - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will test if a different way of giving pain medication before and during surgery can decrease the risk of opioid addiction and improve pain control.

Eligible Conditions
  • Postoperative Pain
  • Urethral Stricture

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 3 weeks

3 weeks
Opioid medication use
Participant pain control: Numerical Rating Scale (NRS)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Standard Protocol
1 of 2
Enhanced Recovery Protocol
1 of 2

Active Control

Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: Bupivacaine · No Placebo Group · Phase 4

Enhanced Recovery ProtocolExperimental Group · 7 Interventions: Ibuprofen 800 mg, Bupivacaine, Acetaminophen, Oxycodone, celebrex, Dexamethasone, Gabapentin · Intervention Types: Drug, Drug, Drug, Drug, Drug, Drug, Drug
Standard ProtocolActiveComparator Group · 3 Interventions: Ibuprofen 800 mg, Acetaminophen, Oxycodone · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibuprofen
FDA approved
Bupivacaine
FDA approved
Acetaminophen
FDA approved
Oxycodone
FDA approved
Celecoxib
FDA approved
Dexamethasone
FDA approved
Gabapentin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 weeks

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,437 Previous Clinical Trials
2,229,284 Total Patients Enrolled
John P Selph, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Eligibility Criteria

Age 18+ · Male Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: